Trial Profile
Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tadalafil (Primary) ; Vardenafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 01 Mar 2017 New trial record